New Drug Dalvance Wins FDA Approval to Treat Skin Infections

May 27, 2014 7:31 PM

11 0

A new antibacterial drug called Dalvance received the U.S. Food and Drug Administration nod to treat adults with skin infection.

In a latest announcement the federal regulators approved Dalbavancin (Dalvance), an antibacterial drug that cures acute bacterial skin and skin structure infections (ABSSSI) caused by bacteria Staphylococcus aurerus and Streptococcus Pyogenes.

Also read: National Cancer Institute Says Researchers Didn’t Quickly Tell FDA After Two Deaths in a Lymphoma Study

Read more

To category page